Mobilizing stem cells from normal donors: is it possible to improve upon G-CSF?

Area of Science:

• Hematology
• Transplantation Immunology
• Pharmacology

Background:

• Granulocyte colony-stimulating factor (G-CSF) is the standard for peripheral blood stem cell (PBSC) mobilization but has side effects and requires multi-day dosing.
• Granulocyte-macrophage colony-stimulating factor (GM-CSF) is approved but can alter graft composition and lead to insufficient CD34+ cell yields or toxicity in some donors.

Purpose of the Study:

• To review current stem cell mobilization strategies in normal donors.
• To discuss novel agents like AMD3100 for peripheral blood stem cell mobilization.

Main Methods:

• Review of existing literature on G-CSF and GM-CSF for stem cell mobilization.
• Analysis of preclinical and clinical data for AMD3100 as a stem cell mobilizing agent.

Main Results:

• AMD3100 mobilizes PBSCs rapidly (hours vs. days) by antagonizing the CXCR4/stromal-derived factor-1 interaction.
• AMD3100 has demonstrated good tolerability with no significant side effects in clinical trials.
• AMD3100-mobilized grafts have shown prompt and stable engraftment in autologous and allogeneic transplantation.

Conclusions:

• AMD3100 presents a promising alternative to G-CSF for donor stem cell mobilization due to its speed and safety profile.
• Novel strategies, including AMD3100, are advancing the field of stem cell mobilization for transplantation.